Puigdellívol-Sánchez Anna, Juanes-González Marta, Calderón-Valdiviezo Ana, Losa-Puig Helena, Valls-Foix Roger, González-Salvador Marta, Lozano-Paz Celia, Vidal-Alaball Josep
Medicina de Familia, CAP Anton de Borja-Centre Universitari, c/Marconi-Cantonada Edison s/n, Consorci Sanitari de Terrassa (CST), 08191 Rubí, Spain.
Human Anatomy and Embryology Unit, Faculty of Medicine, c/Casanova 143, Universitat de Barcelona, 08036 Barcelona, Spain.
Microorganisms. 2024 Dec 13;12(12):2589. doi: 10.3390/microorganisms12122589.
No hospitalizations or deaths occurred in residents with the COVID-19 infection, treated with antihistamines and azithromycin, of two external nursing homes during the first wave. We assessed whether patients receiving chronic antihistamines in our institution showed better clinical evolution. COVID-19 admissions and related deaths in the public Hospital of Terrassa ( = 1461) during the pandemic period (11 March 2020-5 May 2023) and cases ( = 32,888) during the period of full suspicion diagnosis (1 June 2020-23 March 2022) were referred to as the number of chronic treatments (nT) including or not including antihistamines (AntiHm or NOAntiHm), and their vaccination status before the first infection (VAC or NoVAC) in our assigned population ( = 140,681 at March 2020) was recorded. No deaths occurred in patients treated with up to ≤6 nT in the AntiHm group in all ages. A significant reduction in hospital admission was observed in the 2-7 nT groups either below or over 60 years old [Odds Ratio (OR) NoAntiHm/AntiHm = 1.76-1.32, respectively, in NoVAC or VAC (OR = 2.10 overall] and in the older ≥8 nT group (OR = 2.08 in NoVac]. In conclusion, patients with chronic antihistamine prescriptions, alone or with polypharmacy, showed reduced hospital admission and mortality rates, suggesting the safety of antihistamine treatment and the need to confirm its effectiveness in a prospective trial.
在第一波疫情期间，两家外部疗养院中感染新冠病毒且接受抗组胺药和阿奇霉素治疗的居民均未出现住院或死亡情况。我们评估了在本机构接受慢性抗组胺药治疗的患者是否表现出更好的临床病程。将疫情期间（2020年3月11日至2023年5月5日）在特拉萨公立医院的新冠病毒感染住院病例及相关死亡病例（n = 1461），以及在完全疑似诊断期间（2020年6月1日至2022年3月23日）的病例（n = 32,888），按照是否包括抗组胺药（AntiHm或NOAntiHm）分为慢性治疗次数（nT），并记录了我们指定人群（2020年3月时n = 140,681）首次感染前的疫苗接种状况（VAC或NoVAC）。在AntiHm组中，所有年龄段接受≤6次nT治疗的患者均未死亡。在2至7次nT组中，60岁以下或60岁以上人群的住院率均显著降低[未接种疫苗（NoVAC）或接种疫苗（VAC）时，NoAntiHm/AntiHm的比值比（OR）分别为1.76和1.32，总体OR = 2.10]，在年龄较大的≥8次nT组中（未接种疫苗时OR = 2.08）也是如此。总之，开具慢性抗组胺药处方的患者，无论单独用药还是联合用药，住院率和死亡率均有所降低，这表明抗组胺药治疗具有安全性，且有必要在一项前瞻性试验中确认其有效性。
